Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Dyne Therapeutics Stock Performance
Shares of DYN opened at $29.34 on Tuesday. The stock has a 50-day simple moving average of $32.42 and a 200-day simple moving average of $35.26. Dyne Therapeutics, Inc. has a 1 year low of $10.03 and a 1 year high of $47.45. The stock has a market capitalization of $2.99 billion, a PE ratio of -8.24 and a beta of 1.10.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Analysts predict that Dyne Therapeutics, Inc. will post -3.39 EPS for the current year.
Analyst Upgrades and Downgrades
Financial Prophecy
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
Several equities analysts have weighed in on DYN shares. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 15th. Piper Sandler reiterated an "overweight" rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Stifel Nicolaus boosted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a report on Friday, August 16th. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Finally, StockNews.com cut shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.40.
Check Out Our Latest Research Report on DYN
Institutional Trading of Dyne Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the 3rd quarter valued at about $36,000. US Bancorp DE lifted its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after acquiring an additional 1,212 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
